These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8233287)

  • 21. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant propofol for refractory cisplatin-associated nausea and vomiting.
    Borgeat A; Wilder-Smith OH; Wilder-Smith CH; Forni M; Suter PM
    Lancet; 1992 Sep; 340(8820):679-80. PubMed ID: 1355248
    [No Abstract]   [Full Text] [Related]  

  • 23. Control of nausea and vomiting by granisetron in ovarian cancer patients treated with different cisplatin-based regimens.
    Bresciani G; Böhm S; Oriana S
    Tumori; 1994 Oct; 80(5):344-7. PubMed ID: 7839463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis--outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group].
    Ozono S; Okajima E; Hirao YK; Natsume O; Kaneko Y; Ohara S; Tabata S; Watanabe S; Aoyama H; Sasaki K; Matsuki H; Takashima K; Maruyama Y; Yoshikawa M; Yamada K; Momose H; Hiramatsu T; Hayashi Y; Babaya K; Shiomi T
    Gan To Kagaku Ryoho; 1997 Feb; 24(3):349-56. PubMed ID: 9051139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research.
    J Clin Oncol; 1995 Sep; 13(9):2417-26. PubMed ID: 7666102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
    Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
    Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ondansetron in chemotherapy-induced emesis. Our experience.
    Framarino dei Malatesta M; Veneziano M; Fiorelli C; Bandiera AF; Yacoub M; Toccaceli Blasi MR; Marzetti L
    Eur J Gynaecol Oncol; 1995; 16(2):97-106. PubMed ID: 7641745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
    Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy.
    Tsavaris N; Fountzilas G; Mylonakis N; Athanassiadis A; Kosmas C; Karakousis C; Bacoyiannis C; Kosmidis P
    Oncology; 1998; 55(6):513-6. PubMed ID: 9778615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
    Oge A; Alkiş N; Oge O; Kartum A
    J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
    Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F
    Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A randomized cross-over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP-based chemotherapy for gynecologic cancer].
    Wataba K; Sagae S; Fukunaka N; Sugimura M; Akutagawa N; Hayashi T; Yamana K; Nakamura T; Terasawa K; Mizumoto H; Kitajima Y; Kudo R
    Gan To Kagaku Ryoho; 1997 Apr; 24(6):691-7. PubMed ID: 9126306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study.
    Mandalà M; Cremonesi M; Rocca A; Cazzaniga M; Ferretti G; Di Cosimo S; Ghilardi M; Cabiddu M; Barni S
    Support Care Cancer; 2005 Jun; 13(6):375-80. PubMed ID: 15668754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?].
    Lehoczky O; Bagaméri A; Sárosi Z; Kulcsár T; Pulay T
    Orv Hetil; 2001 Aug; 142(31):1681-4. PubMed ID: 11556262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
    Zeng WY
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):273-5. PubMed ID: 1396075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of granisetron for cancer patients undergoing platinum-based chemotherapy: comparison of 1 miligram versus 3 miligram doses in preventing nausea and vomiting.
    Kurnianda J; Hisyam B; Wahyuningsih E; Hutajulu SH
    Acta Med Indones; 2005; 37(4):210-3. PubMed ID: 16317218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
    Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
    Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
    Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
    Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.